A Bispecific Anti-Fluorescein × Anti-CD3 T-cell Engager in Combination with Fluoresceinated Adaptors Enables Lysis of AML Cells
A flexible T-cell therapy platform targeting multiple leukemia antigens simultaneously performed as well as CAR-T in early tests, offering design advantages.
This preclinical study demonstrated that a bispecific anti-FITC × anti-CD3 T-cell engager (AdFITC-TCE) can redirect T cells against AML cells via fluoresceinated adaptor antibodies targeting CD33 or CD117, achieving efficient tumor lysis in vitro and tumor growth inhibition in NSG mice comparable to CAR-T cells. The platform's versatility in simultaneously targeting multiple antigens and enabling on/off switching may address key limitations of current AML-directed CAR-T approaches.
What the study was
- Study design
- Preclinical in vitro + in vivo mouse model study
- Population
- AML cell lines; NOD-SCID-IL2rg (NSG) mice with human AML tumor xenografts
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- Molecular Cancer Therapeutics
Why it surfaced
Novel switchable bispecific TCE for AML with multi-antigen targeting capability; preclinical in vitro + NSG mouse validation. Triage score capped at 5 per non-human study rule (watchlist targets AML treatment broadly but not explicitly preclinical discovery). ETH Zurich / University of Zurich; SNF/ERC-funded.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.